Dr Bardia discusses data from DESTINY-Breast03 (NCT03529110), HER2CLIMB (NCT02614794), and NALA (NCT01808573), important findings that were presented at the 2021 San Antonio Breast Cancer Symposium for patients who have HER2-positive metastatic breast cancer.
